Next Article in Journal
Exploring the Multi-Faceted Potential of Carob (Ceratonia siliqua var. Rahma) Leaves from Morocco: A Comprehensive Analysis of Polyphenols Profile, Antimicrobial Activity, Cytotoxicity against Breast Cancer Cell Lines, and Genotoxicity
Next Article in Special Issue
Covalent Conjugates of Allylbenzenes and Terpenoids as Antibiotics Enhancers with the Function of Prolonged Action
Previous Article in Journal
Intracellular Drug Delivery Process of Am80-Encapsulated Lipid Nanoparticles Aiming for Alveolar Regeneration
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 16
Issue 6
10.3390/ph16060839
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synergy of Plant Essential Oils in Antibiotic Therapy to Combat Klebsiella pneumoniae Infections

by
Mariana Romo-Castillo
1,*,
Victor Andrés Flores-Bautista
2,
Silvia Laura Guzmán-Gutiérrez
3,
Ricardo Reyes-Chilpa
4,
Mayra León-Santiago
4 and
Victor Manuel Luna-Pineda
5
1
CONAHCYT/HIMFG, Laboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City 06720, Mexico
2
Facultad de Estudios Superiores Zaragoza Campus II, Universidad Nacional Autónoma de México, Mexico City 09230, Mexico
3
CONAHCYT/Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
4
Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
5
Laboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City 06720, Mexico
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2023, 16(6), 839; https://doi.org/10.3390/ph16060839
Submission received: 26 April 2023 / Revised: 25 May 2023 / Accepted: 29 May 2023 / Published: 5 June 2023
(This article belongs to the Special Issue Discovery of Novel Plant-Derived Compounds with Antibacterial Activities)
Browse Figures
Versions Notes

Abstract

:
Increased antibiotic resistance presents a health problem worldwide. The World Health Organization published a list of pathogens considered a priority for designing new treatments. Klebsiella pneumoniae (Kp) is a top-priority microorganism, highlighting the strains that produce carbapenemases. Developing new efficient therapies or complementing existing treatments is a priority, and essential oils (EOs) provide an alternative. EOs could act as antibiotic adjuvants and enhance antibiotic activity. Employing standard methodologies, the antibacterial activity of the EOs and their synergic effect with antibiotics were detected. A string test was used to identify the impact of the EOs over the hypermucoviscosity phenotype presented by Kp strains, and Gas Chromatography–Mass Spectrometry analysis identified EOs and the composition of EOs. The potential of EOs for designing synergistic therapies with antibiotics to combat the infection of KPC diseases was demonstrated. In addition, the alteration of the hypermucoviscosity phenotype was shown as the principal mechanism of a synergic action between EOs and antibiotics. The differential composition of the EOs lets us identify some molecules that will be analyzed. Synergic activity of EOs and antibiotics can provide a solid platform for combating multiresistant pathogens that represent a severe health sector problem, such as Kp infections.

1. Introduction

Infection diseases are responsible for many illnesses and death worldwide, and last year, the World Health Organization reported high levels of resistant antimicrobial bacteria diseases in many countries. Principally, bloodstream infections caused by Klebsiella pneumoniae and Acinetobacter spp. increased above 50% (https://www.who.int/news/item/17-01-2020-lack-of-new-antibiotics-threatens-global-efforts-to-contain-drug-resistant-infections, accessed on 12 April 2023). Klebsiella pneumoniae (Kp) is a Gram-negative, encapsulated bacteria that possesses a lot of virulence factors (fimbriae, porins, siderophores, efflux pumps, type VI secretion system, biofilm, etc.) [1,2]. Kp is an opportunist pathogen that can cause infections at multiple sites such as the lung, urinary tract, bloodstream, brain, respiratory tract, and liver [3,4,5,6,7,8,9]. Its capsule acts as a protective shield that can avoid bactericidal action. In addition, the capsule is responsible for the viscosity and hypermucoviscosity phenotype of the strains cultured in nutrient media [10,11]. The genes involved in capsule synthesis are in a chromosomal pathogenesis island named the cps locus [12]. The capsule is involved in the resistance because it limits the interaction of antimicrobial molecules with the bacterial surface. The compounds that inhibit the capsule might help render capsulated bacteria [13].
Many Kp strains present an hypermucoviscosity phenotype, defined as when strains produce a thick filament of ~5 mm by the “string test”. This phenotype is commonly associated with infections such as bacteremia, liver abscesses, meningitis, and endophthalmitis [14]. The genes magA and rmpA have been associated with this phenotype [15,16]. It is important to remark that the hypervirulence of the strains is not always related to the hypermucoviscosity phenotype, but information about this correlation remains in continuous discussion. Some groups characterized hypervirulent strains (hvKP), identifying that only 60% have a hypermucoviscosity phenotype, but virulence between strains is comparable. This finding suggested that, contrary to the initial idea that hvKP strains possess an hypermucoviscosity phenotype hypervirulence is an additive characteristic of the strains, independent of their viscosity [17]. More studies are needed to understand the bacterial genetic factors responsible for the hypervirulent phenotype. Additionally, it is essential to note that the overexpression of many virulence factors, such as siderophores, capsules, lipopolysaccharides, and biofilm, causes the hyperviscosity phenotype.
The emergence of multidrug-resistant Kp strains has become a significant medical problem. Kp is intrinsically resistant to ampicillin because it possesses a penicillinase codified in its genome [18]. Kp develops antibiotic resistance faster than other strains because of its ability to acquire multiple mobile plasmids by horizontal transfer [19]. This genomic plasticity makes antibiotic therapies ineffective and indicates the need for developing alternative therapies against this pathogen. Many studies have demonstrated the prevalence and antibiotic resistance of Kp in strains. In Hangzhou, China, antibiotic resistance and the ratio of Kp cases increased by 30% in 2020 compared to 2006 [20]. A bloodstream infection analysis identified a significant increase in colistin Kp-resistant strains in recent years compared to the pre-SARS-CoV-2 period in many countries such as Brazil, China, India, Pakistan, Peru, South Korea, and Thailand [21]. Although antibiotic therapy is ineffective against SARS-CoV-2 infection, some studies stated that 70% of hospitalized patients received high-spectrum antibiotic therapy [22]. The main limitation in developing new antibiotics is financial efficiency. Since 2011, academics, organizations, and the pharmaceutical industry established that one of the potential strategies to combat antibiotic resistance is the development of antibiotic adjuvants.
Recently, natural-origin compounds, such as plant extracts and essential oils (EOs), have received particular attention because of their properties, economic viability, and efficacy. EOs are volatile molecules with antibacterial, anti-inflammatory, and antioxidant properties that effectively combat many diseases. EOs are synthesized by all plant organs (buds, flowers, leaves, stems, seeds, fruits, roots, etc.). Generally, EOs are liquid at room temperature, but some can be solid or have a resinous texture. The principal antibacterial activity of the EOs is caused by their chemical composition, principally by the presence of terpenoids. The global composition of EOs can vary in response to seasonal variation, culture conditions, the clime, and even the oil extraction method [23]. This variability is essential to consider because it can affect their antibacterial activity and the standardization of their application. However, EOs could be the best option to combat biofilm- and capsulated-related bacterial infections when compared with other plant-origin compounds. EOs can disrupt the bacterial capsule by their hydrophobicity, interact with the lipids, and disrupt the barrier making bacterial cells more accessible and permeable [24].
The effective antimicrobial efficacy of EO combinations has already been demonstrated [25]. However, the synergy between antimicrobial agents, plant extracts, and EOs is a new concept that has yet to be studied. A positive effect has been observed in using tetracycline and erythromycin with ethanolic mango peel extract (Mangifera indica) against S. aureus [26,27,28]. The methanolic extract of Damascus rose (Rosa damascena) decreases the minimum inhibitory concentration (MIC) of tetracycline against P. aeruginosa [29]. The effect of reducing the antibiotic MIC and their effective activity against some bacteria supports the idea that EOs could be used as an effective adjuvant to combat many bacterial diseases. This study aimed to demonstrate the potential of EOs to combat Klebsiella pneumoniae diseases as synergic therapy for antibiotics. This therapy could be successful for all Kp infections regardless of their antibiotic resistance or virulence level.

2. Results

2.1. Chemical Composition of EOs

Thirty-five plant EOs were screened to identify the best oil against Kp (data not shown), and only four EOs were included in this study (Table 1). A local producer from Coyoacan, Mexico City, Mexico, provided all EOs.
General major compounds of the essential oils were identified by comparison with available authentic samples. Still, their Kováts retention index was also obtained and compared with the reported data, supporting our chemical characterization of the tested oils. The major constituents of the EOs have been compiled in Table 2.
The major constituents of thyme EO were thymol (37.31%), o-Cymene (22.12%), and γ-Terpinene (11.97%) with a retention time (rt) between 8.4 to 13.3 and a match of 98.4 to 99.5; the minor constituent was p-Mentha-2,4(8)-diene (0.25%) with an rt of 9.63 and a match of 88.2. For rosemary EO, major constituents were eucalyptol (43.28%), (+)-2-Bornanone (13.34%), and α-pinene (13.17%), with an rt between 6.61 to 10.74 and a match of 99.3 to 99.8; while the minor constituent was isoterpinolene (0.31%) with an rt of 9.64 and a match of 91.7. For peppermint, the EO was composed majorly of menthol (38.19%), D-menthone (22.96%), and p-Mmenthan-1-ol (8.39%) with a retention time (rt) between 10.91 and 11.20 and a match of 95.2 to 99.8; the minor constituent was cis-Muurola-4(14), 5-diene (0.25%) with an rt of 16.45 and a match of 83.5. Finally, major constituents of turmeric EO were ar-turmerone (40.40%), turmerone (16.36%), and α-Curcumene (4.53%) with a retention time (rt) between 16.50 and 19.28 and a match of 97.7 to 99.0; the minor constituent was (+)-4-Carene (0.21%) with an rt of 9.64 and a match of 88.6.

2.2. Antimicrobial Activity of EOs against Kp Strains

The antimicrobial activity of the EOs was tested against Kp clinical strains. These clinical strains were grouped following their antibiotic resistance profile in susceptible (Low Resistant Strain, LRS), intermediate (Medium Resistant Strain, MRS), and resistant (High Resistant Strain, HRS) groups. The antimicrobial activity test was performed by disc diffusion test in Mueller–Hinton agar. Inhibition ratios were measured for the four EOs, Ceftazidime, and dimethyl sulfoxide (DMSO). DMSO was used as an organic solvent to prepare dilutions and facilitate the solubilization of the EOs. The antimicrobial effect of the EOs was considered efficient when the tests showed a ratio ≥ of 15 mm, which was the breakpoint reported for Ceftazidime by the Clinical Laboratory Standards Institute (CLSI; https://clsi.org, accessed on 8 December 2022). A great antimicrobial activity by EOs was identified against all strains regardless of their antimicrobial resistance profile (Figure 1). Thyme EO has the best antimicrobial activity compared to other EOs and Kp clinical strains (p < 0.01) (Figure 1A). Turmeric, rosemary, and peppermint EOs have the same inhibition ratios as well as susceptible Kp strains; nevertheless, a significant statistical difference (p < 0.01) was identified when they were analyzed with intermediate and resistant Kp strains (Figure 1B,C).
A serial dilution test determined each EO’s minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). The MIC and the MBC vary in each group, regardless of its level of antibiotic resistance. Thyme is the best EO against Kp strains, with an MIC median of 0.15% (v/v) and an MBC median of 0.45%. Peppermint is another EO with bacteriostatic and bactericidal activity, with an MIC median of 0.60% and an MBC median of 1.25%. Rosemary EO had an MIC median of 0.45% and an MBC median of 3.75%, while turmeric had an MIC median of 2.50% and an MBC median of 6.25% (Figure 2). Non-statistical differences were shown between MIC and MBC groups.

2.3. Synergic Effect of EOs with Ceftazidime (CAZ)

Antibiotics are the primary therapy used to control Kp infections; however, they are losing effectiveness. The hypermucoviscosity of Kp strains affects antibiotic diffusion and activity, affecting the control of these diseases. A checkerboard assay was performed to analyze the synergic effect that EOs could have with antibiotic therapy. The first antibiotic used was Ceftazidime (CAZ), recommended to control urinary diseases and nosocomial-associated pneumonia. The MIC median of CAZ was 32 μg/mL, and its MBC median was 10 μg/mL, but if an EO is combined with an antibiotic, the MIC and MBC values decrease significatively (p < 0.5) (Figure 3). Interestingly, the combination of CAZ and thyme was lethal to all the strains, still in very low concentrations of 0.12 μg/mL: 0.1% (CAZ:thyme). Peppermint EO at 0.22% reduced the CAZ MIC median to 0.5 μg/mL and MBC median to 0.38 μg/mL. Rosemary at 0.22% reduced the CAZ MIC median to 0.75 μg/mL and MBC median to 1.50 μg/mL. In comparison, turmeric at 0.63% decreased CAZ MIC median to 0.50 μg/mL and MBC median to 2.00 μg/mL (Figure 3).
When the Fractional Inhibitory Concentration Index (FICI) was calculated for each combination, a synergic effect was demonstrated between CAZ + thyme, with a FICI mean of 0.250, and in the CAZ + peppermint mixture, with a FICI mean of 0.357. At the same time, turmeric and rosemary EOs present only an additive effect with FICI mean between 0.536 to 0.545 (Table 3).

2.4. Synergic Effect of EOs with Gentamicin (GEN)

To identify the potential of EOs as synergic therapy with antibiotics, a second EO antibiotic was probed. The second antibiotic analyzed was Gentamicin (GEN), used for severe blood, bone, gastrointestinal, urinary, and meningitis infections. For this experiment, strain 889U (sensible to GEN), strain 98LCR (intermediately resistant to GEN), and strain 197U (resistant to GEN) were employed. The principal limitation to analyzing more strains is that our collection lacks other intermediate strains. The MIC median of GEN was 8 μg/mL, and it had an MBC median of 16 μg/mL, but EOs combined with an antibiotic decreased the MIC and MBC values of GEN (p < 0.5) (Figure 4). The combination of GEN and thyme was not lethal, but in 0.08% of Thyme EO, the MIC and MBC of GEN decreased to 16 μg/mL. Peppermint EO at 0.30% reduced the GEN MIC median to 1.0 μg/mL and its MBC median to 2.0 μg/mL. Rosemary at 0.15% reduced GEN MIC and MBC medians to 2.0 μg/mL. Finally, turmeric at 1.25% decreased GEN MIC median to 1.0 μg/mL and MBC median to 2.00 μg/mL.
When the Fractional Inhibitory Concentration Index (FICI) was calculated for each EO combination with GEN, a synergic effect was demonstrated between GEN + peppermint with a FICI mean of 0.275, GEN + thyme with a FICI mean of 0.410, and GEN + rosemary mixture with a FICI mean of 0.458. Turmeric presented an indifferent effect with GEN with a FICI mean of 1.083 (Table 4).

2.5. Synergic Effect of EOs with Ciprofloxacin (CIP)

Finally, a third antibiotic was probed. Ciprofloxacin (CIP) treats urinary tract infections, pneumoniae, and skin and bone infections. For this experiment, two new strains were employed (817LCR and 910LCR) because all of the strains included those who are sensible to CIP. Although 817LCR and 910LCR strains have no complete antibiotic profile, intermediate and resistant profiles to CIP were detected, respectively. As for previously analyzed antibiotics, results demonstrated that EOs decrease CIP MIC and MBC (Figure 5). The MIC median of CIP was 0.5 μg/mL, and its MBC median was 2 μg/mL. Interestingly, as found for CAZ, the combination of CIP and thyme was lethal to all the strains, still in very low concentrations of 0.15 μg/mL:0.08% (CIP:thyme). Peppermint EO at 0.30% reduced the CIP MIC median to 0.125 μg/mL and the MBC median to 0.30 μg/mL. Rosemary at 0.15% reduced the CIP MIC median to 0.10 μg/mL and MBC median to 1.00 μg/mL. In comparison, turmeric at 0.1.25% decreased the CIP MIC median to 0.06 μg/mL and the MBC median to 0.13 μg/mL (Figure 5).
When the Fractional Inhibitory Concentration Index (FICI) was calculated for each EO combination with CIP, a synergic effect was demonstrated between CIP + peppermint with a FICI mean of 0.3.11, CIP + thyme with a FICI mean of 0.389, and CIP + rosemary mixture with a FICI mean of 0.459. Turmeric presents an additive effect with CIP with a FICI mean of 0.835 (Table 5).

2.6. Effect of EOs over the Hypermucoviscosity Phenotype of Kp Strains

The emergence of Kp hypermucoviscosity strains is associated with the increasing antibiotic resistance phenotype. The hypermucoviscosity phenotype enhances resistance to antibiotics by minimizing the binding of antibiotics to the bacterial surface [30]. To understand EOs’ action mechanism, their effect on the hypermucoviscosity phenotype was evaluated by a string test. Results demonstrate that EOs can decrease the hypermucoviscosity phenotype in all the strains, and some EOs can even eliminate it, such as thyme (Figure 6). Turmeric EO reduces the hypermucoviscosity with a mean of 84.56 ± 14.98% (in a range of 67.05 to 100%), rosemary EO decreases the hypermucoviscosity with a mean of 82.84 ± 23.98% (in a range of 39.29 to 100%), and peppermint EO reduce the hypermucoviscosity with a mean of 82.06 ± 18.65% (in a range of 42.61 to 100%). This effect on the hypermucoviscosity phenotype is independent of the bacterial resistance pattern. This result could suggest that the physical barrier presented by this hypermucoviscosity phenotype could make bacteria more vulnerable to environmental stimuli such as the presence of antimicrobial agents.

3. Discussion

Antibiotic resistance is a global problem that affects the health sector. The principal origin of antibiotic resistance appears to be from extended hospital stays and indiscriminate antibiotic use. The SARS-CoV-2 pandemic could influence the emergence of multiresistant pathogens because of the uncontrolled application of antibiotics. Kp is a common opportunist pathogen causing many hospital-patient-associated infections, and its antibiotic resistance is increasing faster than expected. The treatment of Kp-associated diseases has become problematic because of the emergence of multidrug-resistant strains. For this reason, it is included at the top of the priority list of the WHO to develop new treatments against, and plant-origin compounds are gaining attention.
Plant-origin compounds provide many opportunities to identify and design new effective therapies against multiresistant bacterial infections. EOs gained interest as an effective alternative against multiresistant diseases. Initial screening with 35 EOs was performed, but only 4 were included owing to their inhibition ratio >15mm, which were thyme, turmeric, rosemary, and peppermint EOs. These EOs’ bactericidal activity is comparable with antibiotics and acts against HRS, and their composition is similar to other EOs. Although EOs are a product of the secondary metabolism of plants, which are produced to make plants competitive in their environment, many factors could affect their chemical composition. These factors are classified into exogenous and endogenous factors. The exogenous factors are the environmentally regulated factors, such as light, precipitation, growing site, and soil, which might modify the amount of the volatile compounds of the EOs. The endogenous factors are strictly related to the anatomical and physiological characteristics of the plants linked to the chemical variation metabolism of the different parts of the plant, the development stage, and the genetically related factors [23,31]. Other factors that can influence the composition of an EO are the extraction method, the selection of the solvent used for the extraction, the application of pre-distillation treatments, and the temperature used in the extraction, as well as the mechanical and physical conditions used for the obtaining and conservation of the plant samples before the extraction of the EO [32,33]. Thymol is thyme’s major component; in other studies, it has shown inhibitory effects against Gram-negative and Gram-positive bacteria strains [33,34]. Thyme is the best option for designing a synergic therapy against Kp infections considering the results obtained in this study. Eucalyptol was identified as a significant component of rosemary EO and has been demonstrated to inhibit the growth of bacteria such as S. aureus, P. aeruginosa, E. coli, E. faecalis, and Kp ATCC 700603, as well as the yeast C. albicans [35]. Menthol is another component with antimicrobial activity against pathogenic and non-pathogenic microorganisms, such as S. aureus, S. mutans, E. faecalis, S. pyogenis, L. acidophilus, P. aeruginosa, and the yeast C. albicans [36]. It was the major component of Peppermint EO. Ar-turmerone is the major component of turmeric EO and has anti-inflammatory, anti-plasmodial, neuroprotective, and anti-aging activities. Nevertheless, there are indications of its antioxidant and antibacterial activity. The composition of thyme EO was comparable with the composition previously reported, although the amount of some components in other EOs differs [37]. For rosemary EO, the amount of Linalool (13.34%) was higher for other reports that present 0.4–0.5% [38,39]. Peppermint EO presents more p-Menthan-1-ol (8.39%) than other reports, with only 0.3–0.9% [40]. Curcumin has been reported as the main component of turmeric; however, ar-turmerone was identified in this study [41]. Recognizing the potential of plant-origin compounds can lead us to develop new strategies quickly that help us combat multiresistant diseases. Despite the differences identified in the concentration of some compounds, it is essential to determine the presence of these compounds to identify the molecules responsible for the antimicrobial activity that has been reported. This information will help identify specific EO molecules that can be used to combat different pathogens and, in combination with other compounds, in the appropriate concentrations, favor the design of synergistic therapies and allow their implementation at an industrial level. Metabolic engineering and nanotechnology have significantly advanced the synthesizing of some specific compounds, created release systems, and even obtaining synthetic EOs with natural EOs’ benefits.
The top result in this study was the synergic effect that EOs have with antibiotics of different families, such as aminoglycosides, quinolones, and cephalosporins. However, the synergic effect of the EOs is different. The best synergic effect between EOs and antibiotics was confirmed for thyme with CAZ and peppermint for GEN and CIP. CAZ is a third-generation cephalosporin that inhibits enzymes responsible for cell wall synthesis. Gentamicin is an aminoglycoside that produces membrane disruption and impaired protein synthesis. CIP is a second-generation fluoroquinolone that blocks DNA gyrase and Topoisomerase IV activities, preventing DNA replication [42]. A study using eucalyptol, amoxicillin/clavulanic acid (AMC), and Gentamicin showed a synergistic effect against S. aureus from osteomyelitis patients when compared with the combination of AMC with Gentamicin, which did not produce an impact [43]. The study supports the claim of the initial analysis using alternative plant compounds, such as EOs, to design alternative and complementary therapies to combat Kp diseases. The results suggest that a mixture of low concentrations of antibiotics and EO combinations could fight Kp infections, even if multiresistant or hypermucoviscosity strains cause them. It supports the idea that EOs affect the physical barrier responsible for the hypermucoviscosity phenotype allowing the internalization of antibiotics and acting against the pathogen. The complex composition of EOs in bioactive components and their liposoluble nature helps penetrate the biofilm, capsule, and bacterial membranes, altering multiple pathways that help control many diseases [44]. A comparison of the antimicrobial activity of EOs with sensitive, intermediate, and resistant Kp strains shows similar levels of activity, suggesting that the mechanisms used by bacteria to generate resistance to antibiotics are inefficient in providing resistance to EOs. These approaches also could help design therapies, nanoparticles, and textiles useful in biomedicine to control and combat other bacterial infections and reduce the use of antibiotics [45,46,47]. The therapeutic efficacy of Gentamicin and Ceftazidime co-encapsulated into liposomes showed an additive effect on rat survival, followed by a single dose or as a 5-day treatment [48].
This study has some limitations that should be considered. Although the direct effect of EOs against Kp is tested during this study, it is necessary to analyze if the volatile compounds present during evaporative diffuser use have the same effect. Commonly, EO application is performed through these kinds of diffusers, and the dosage and composition of airborne components will change and modify EO antimicrobial activity, so future studies are needed to analyze the employment of EO synergic treatment through aerial administration to combat respiratory infections caused by Kp. However, this study provides strong evidence of synergic EO therapy’s effectiveness.

4. Materials and Methods

4.1. Essential Oils

The essential oils were obtained from a local Coyoacan, México City, producer. The plants were cultivated in organic conditions (without synthetic fertilizers and pesticides), and essential oils were obtained by steam distillation following published methodology [49] from their leaves, stems, flowers, and rhizomes, as described in Table 1. The oils were collected, deposited in amber vials, and stored at 4 °C.

4.2. Chemical Analysis

The essential oil in chloroform solution was analyzed by gas chromatography (GC) using an Agilent 7890N coupled to an Agilent Technologies 5977A mass spectrometer GC(MS). The injection volume was 1 µL, split 20:1. The capillary column was an HP5-ms 30 m × 250 µm ID × 0.25 µm film thickness; the carrier gas was helium, flow rate, 1 mL/min; oven temperature range was from to 40 to 300 °C (Program: 40 °C, 1 min ramp 1, 8 °C/min; 200 °C, 1 min ramp 2, 15 °C/min; 300 °C, 2 min) along 4 min; injector temperature was 280 °C; and detector temperature was 310 °C. Mass spectra were registered over m/z 30–600 using an ionizing voltage of 70 eV. The essential oil constituents were characterized by matching their mass spectra with the compound library NIST (National Institute of Standards and Technology, U.S. Department of Commerce, Gaithersburg, MD, USA). The alkanes C8 to C24 were used to calibrate the Kováts scale (lineal retention indices), and experimental results were compared with reported data (NIST). The monoterpenes α-pinene, β-pinene, 3-carene, D-limonene, eucalyptol, γ-terpinene, linalool, α-terpineol, citronellol, nerol, L-carvone, linalyl acetate, thymol, carvacrol, neryl acetate, and geranyl acetate were also identified by comparison with mass spectra of authentic samples.

4.3. Microorganisms

Klebsiella pneumoniae clinical strains were used to analyze the potential of EOs. Previously characterized strains [50] were classified and selected based on their resistance pattern (Table 6). Low-resistance strains (LRSs) were defined as strains that are sensitive to Ceftazidime and only are resistant to one antibiotic. Medium-resistance strains (MRSs) are intermediately resistant to Ceftazidime (CAZ) and five other antibiotics. Last, high-resistance strains (HRSs) were defined as resistant to CAZ and seven other antibiotics. The antibiotics analyzed were cefpodoxime (10 μg), ceftazidime (30 μg), cefepime (30 μg), ceftriaxone (30 μg), aztreonam (30 μg), Gentamicin (10 μg), amikacin (30 μg), ciprofloxacin (5 μg), ofloxacin (10 μg), meropenem (10 μg), imipenem (10 μg), and trimethoprim/sulfamethoxazole (1.25/23.75 μg) by the Kirby–Bauer method. Resistance patterns were determined according to the Clinical Laboratory Standards Institute (https://clsi.org, accessed on 8 December 2022). The K. pneumoniae ATCC 700603 strain was used as a control. Three LRSs (640U, 889U, and 126U), three MRSs (98LCR, 338U, 160D), and three HRSs (971U-1, 197U, and 182D) were included in the first part of the study. Then, two strains were added for Ciprofloxacin synergy analysis because of their intermediate (817LCR strain) and resistant (910LCR strain) pattern against CIP, although they possessed an incomplete antibiogram analysis. Strains were grown in Brain Heart Infusion agar (BHI) at 37 °C for 18 h.

4.4. Antimicrobial Activity Test

Antibacterial activity against Kp strains was evaluated by the disk diffusion method in Mueller–Hinton Agar (MHA). Briefly, each strain was cultured in 5 mL of Mueller–Hinton broth (MHB) for 18 h at 37 °C and 150 rpm. Then, overnight cultures were diluted at a turbidity of 0.5 McFarland (108 CFU/mL). Then, 100 μL of the bacterial inoculum was uniformly spread in MHA, and blank-standard disks were impregned with 10 μL of each EO. Plates were incubated at 37 °C for 18 h. Inhibition of bacterial growth was measured in mm. Tests were performed in triplicate. Commercial discs of Ceftazidime (CAZ, 30 μg) were used as a reference.
In addition, a microdilution test was performed to determine the Minimum Inhibitory Concentration (MIC) and the Minimum Bactericidal Concentration (MBC). Serial dilutions of the EOs dissolved in DMSO were performed to obtain different concentration rates (from 40 to 0.07%(v/v)). Then, 50 μL of each dilution added to 50 μL of MHB was inoculated with 50 μL of bacteria broth adjusted to 0.5 McFarland (106 CFU/mL) using 96-well microplates. After 24 h of incubation at 37 °C, MIC analysis was performed. In addition, 10 μL of each sample was subcultured onto MHA and incubated for 24 h at 37 °C to determine MBC. The concentration without visible growth was defined as the MIC, while the concentration without colony growth was considered as the MBC. Additionally, analysis for the MIC and MBC of antibiotics were performed using a concentration range from 256 to 0.25 μg/mL for CAZ and GEN and from 32 to 0.03 for CIP. It is important to remark that DMSO does not inhibit bacterial growth (data not shown).

4.5. Synergy between EOs and Antibiotics

For synergy analysis, a checkerboard assay was performed MHB with each EO. Oils were used at subinhibitory concentration dilutions (one quarter of the MIC was used), while antibiotics were used at the gradients described in the Materials and Methods section. Then, the assay was performed as previously described [51]. The fractional inhibitory concentration (FIC) for each EO and antibiotic was calculated by dividing the MIC of two drugs in combination with the MIC of each drug alone. The FIC Index (FICI), the sum of the FICs of each drug, was used to confirm the interaction of the two drugs. The FICI was considered as a synergistic effect if its value was ≤0.5, additive if it was from >0.5 to ≤1, indifferent if it was from >1.0 to ≤4, and antagonistic if it was >4. The experiments were carried out in triplicate, and results were expressed as the arithmetic mean of the three determinations.

4.6. EO Activity on Hypermucoviscosity Phenotype of the Strains

To identify the effect of EOs on hypermucoviscosity of the strains, they were analyzed by string test. Fresh colonies were cultured overnight on blood agar plates in subinhibitory concentrations of each EO and without them. Then, colonies were stretched outward by gently touching them with a loop, and the mucus filament length was measured.

4.7. Statistical Analysis

Results of this study are presented using means and standard deviations of triplicate assays. ANOVA and Tukey’s HSD post hoc analysis of variance were used to manage multiple comparisons. A significant difference was defined when p value was less than 0.05.

5. Conclusions

Antibiotics are considered the best therapy to combat bacterial infections, such as those caused by Kp. However, the rapid increase in resistance requires the development of new alternative therapies or synergistic therapies that help us combat these diseases. Essential oils represent a great tool in the development of synergistic therapies. This study demonstrates the potential of thyme, rosemary, and mint essential oils as synergistic therapies against Kp. Essential oils alter the hypermucoviscosity phenotype of the strains, breaking the lipid-soluble barrier that prevents the internalization and action of antibiotics (Figure 7). Once these factors are modified, antibiotics and essential oils can enter the pathogen and induce its death. This finding will allow us to develop a synergistic therapy to combat the infection caused by Kp regardless of the level of virulence, its resistance capacity, or hypermucoviscosity phenotype.

Author Contributions

Conceptualization, M.R.-C. and S.L.G.-G.; methodology: M.R.-C., S.L.G.-G., R.R.-C. and V.A.F.-B.; formal analysis: M.R.-C., S.L.G.-G. and V.M.L.-P.; investigation: M.R.-C., V.A.F.-B., S.L.G.-G. and M.L.-S.; resources: M.R.-C. and R.R.-C.; writing—original draft preparation: M.R.-C. and V.M.L.-P.; writing—review and editing: all authors. All authors have read and agreed to the published version of the manuscript.

Funding

This research was partially funded by Universidad Nacional Autónoma de México, grant number IG-200418, and Hospital Infantil de México Federico Gómez, project HIM-2020-060 SSA-1686.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article.

Acknowledgments

Thanks to the Intestinal Bacteriology Research Laboratory from the Hospital Infantil de México Federico Gómez who provided us with the Kp strains. We are grateful to Delia Aimee Espinoza Moreno for providing us with the essential oil samples to perform this work. We also thank Everardo Tapia and Marisol Reyes for their chemical technical assistance. The authors extend their appreciation to Consejo Nacional de Humanidades, Ciencia y Tecnología (CONAHCyT), Hospital Infantil de México Federico Gómez (HIM-2020-060 SSA-1686), and Universidad Nacional Autónoma de México for supporting this study (DGAPA-PAPIIT-UNAM, Project IG-200321 IG-200418).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Clegg, S.; Murphy, C.N. Epidemiology and Virulence of Klebsiella Pneumoniae. Microbiol. Spectr. 2016, 4. [Google Scholar] [CrossRef] [Green Version]
  2. Vuotto, C.; Longo, F.; Balice, M.P.; Donelli, G.; Varaldo, P.E. Antibiotic Resistance Related to Biofilm Formation in Klebsiella Pneumoniae. Pathogens 2014, 3, 743–758. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Zhao, J.; Huo, T.; Luo, X.; Lu, F.; Hui, S.; Yang, B. Klebsiella Pneumoniae-Related Brain Abscess and Meningitis in Adults: Case Report. Medicine 2022, 101, e28415. [Google Scholar] [CrossRef] [PubMed]
  4. Jajić, I.; Benčić, A.; Siroglavić, M.; Zarfel, G.; Ružić, B.; Pezelj, I.; Bedenić, B. Klebsiella Pneumoniaeoxa-48 in a Urology Patient: Case Report. Acta Clin. Croat. 2017, 56, 166–171. [Google Scholar] [CrossRef] [Green Version]
  5. Kano, Z.; Onoyama, S.; Tsuji, M.; Tezuka, J.; Furuno, K. Klebsiella Pneumoniae-Associated Septic Pulmonary Emboli in a Healthy Child. Pediatr. Int. 2018, 60, 663–665. [Google Scholar] [CrossRef]
  6. Sturm, E.; Tai, A.; Lin, B.; Kwong, J.; Athan, E.; Howden, B.P.; Angliss, R.D.; Asaid, R.; Pollard, J. Bilateral Osteomyelitis and Liver Abscess Caused by Hypervirulent Klebsiella Pneumoniae- a Rare Clinical Manifestation (Case Report). BMC Infect. Dis. 2018, 18, 380. [Google Scholar] [CrossRef]
  7. Bilal, S.; Volz, M.S.; Fiedler, T.; Podschun, R.; Schneider, T. Klebsiella Pneumoniae-Induced Liver Abscesses, Germany. Emerg. Infect. Dis. 2014, 20, 1939–1940. [Google Scholar] [CrossRef]
  8. Taglietti, F.; Di Bella, S.; Galati, V.; Topino, S.; Iappelli, M.; Petrosillo, N. Carbapenemase-Producing Klebsiella Pneumoniae-Related Mortality among Solid Organ-Transplanted Patients: Do We Know Enough? Transpl. Infect. Dis. 2013, 15, E164–E165. [Google Scholar] [CrossRef]
  9. Wang, B.; Zhang, P.; Li, Y.; Wang, Y. Klebsiella Pneumoniae-Induced Multiple Invasive Abscesses: A Case Report and Literature Review. Medicine 2019, 98, e17362. [Google Scholar] [CrossRef] [PubMed]
  10. Baykara, B.; Cimentepe, M.; Kandemir, T.; Koksal, F. Investigation of the Relationship between Colistin Resistance and Capsule Serotypes in Carbapenem Resistant Klebsiella Pneumoniae Strains. New. Microbiol. 2022, 45, 124–129. [Google Scholar] [PubMed]
  11. Zhang, M.; Zhang, J.; Li, J.; Wu, X.; Xiao, L.; Liu, X.; Yang, X.; Yang, L.; Zou, Q.; Huang, W. AmpR Increases the Virulence of Carbapenem-Resistant Klebsiella Pneumoniae by Regulating the Initial Step of Capsule Synthesis. Infect. Drug. Resist. 2020, 13, 3431–3441. [Google Scholar] [CrossRef] [PubMed]
  12. Pan, Y.-J.; Fang, H.-C.; Yang, H.-C.; Lin, T.-L.; Hsieh, P.-F.; Tsai, F.-C.; Keynan, Y.; Wang, J.-T. Capsular Polysaccharide Synthesis Regions in Klebsiella Pneumoniae Serotype K57 and a New Capsular Serotype. J. Clin. Microbiol. 2008, 46, 2231–2240. [Google Scholar] [CrossRef] [Green Version]
  13. Campos, M.A.; Vargas, M.A.; Regueiro, V.; Llompart, C.M.; Albertí, S.; Bengoechea, J.A. Capsule Polysaccharide Mediates Bacterial Resistance to Antimicrobial Peptides. Infect. Immun. 2004, 72, 7107–7114. [Google Scholar] [CrossRef] [Green Version]
  14. Lee, H.C.; Chuang, Y.C.; Yu, W.L.; Lee, N.Y.; Chang, C.M.; Ko, N.Y.; Wang, L.R.; Ko, W.C. Clinical Implications of Hypermucoviscosity Phenotype in Klebsiella Pneumoniae Isolates: Association with Invasive Syndrome in Patients with Community-Acquired Bacteraemia. J. Intern. Med. 2006, 259, 606–614. [Google Scholar] [CrossRef]
  15. Struve, C.; Bojer, M.; Nielsen, E.M.; Hansen, D.S.; Krogfelt, K.A. Investigation of the Putative Virulence Gene MagA in a Worldwide Collection of 495 Klebsiella Isolates: MagA Is Restricted to the Gene Cluster of Klebsiella Pneumoniae Capsule Serotype K1 [1]. J. Med. Microbiol. 2005, 54, 1111–1113. [Google Scholar] [CrossRef] [PubMed]
  16. Yu, W.L.; Ko, W.C.; Cheng, K.C.; Lee, H.C.; Ke, D.S.; Lee, C.C.; Fung, C.P.; Chuang, Y.C. Association between RmpA and MagA Genes and Clinical Syndromes Caused by Klebsiella Pneumoniae in Taiwan. Clin. Infect. Dis. 2006, 42, 1351–1358. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Togawa, A.; Toh, H.; Onozawa, K.; Yoshimura, M.; Tokushige, C.; Shimono, N.; Takata, T.; Tamura, K. Influence of the Bacterial Phenotypes on the Clinical Manifestations in Klebsiella Pneumoniae Bacteremia Patients: A Retrospective Cohort Study. J. Infect. Chemother. 2015, 21, 531–537. [Google Scholar] [CrossRef]
  18. Sutaria, D.S.; Moya, B.; Green, K.B.; Kim, T.H.; Tao, X.; Jiao, Y.; Louie, A.; Drusano, G.L.; Bulitta, J.B. First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella Pneumoniae. Antimicrob. Agents Chemother. 2018, 62, e00282-18. [Google Scholar] [CrossRef] [Green Version]
  19. Wyres, K.L.; Holt, K.E. Klebsiella Pneumoniae as a Key Trafficker of Drug Resistance Genes from Environmental to Clinically Important Bacteria. Curr. Opin. Microbiol. 2018, 45, 131–139. [Google Scholar] [CrossRef]
  20. Lin, Z.; Yu, J.; Liu, S.; Zhu, M. Prevalence and Antibiotic Resistance of Klebsiella Pneumoniae in a Tertiary Hospital in Hangzhou, China, 2006–2020. J. Int. Med. Res. 2022, 50, 03000605221079761. [Google Scholar] [CrossRef]
  21. Uzairue, L.I.; Rabaan, A.A.; Adewumi, F.A.; Okolie, O.J.; Folorunso, J.B.; Bakhrebah, M.A.; Garout, M.; Alfouzan, W.A.; Halwani, M.A.; Alamri, A.A.; et al. Global Prevalence of Colistin Resistance in Klebsiella Pneumoniae from Bloodstream Infection: A Systematic Review and Meta-Analysis. Pathogens 2022, 11, 1092. [Google Scholar] [CrossRef]
  22. Rawson, T.M.; Zhu, N.; Ranganathan, N.; Gilchrist, M.; Satta, G.; Cooke, G.; Holmes, A. Bacterial and Fungal Co-Infection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing Timothy. Clin. Infect. Dis. 2020, 71, 2459–2468. [Google Scholar]
  23. Barra, A. Factors Affecting Chemical Variability of Essential Oils: A Review of Recent Developments. Nat. Prod. Commun. 2009, 4, 1147–1154. [Google Scholar] [CrossRef] [Green Version]
  24. Jafri, H.; Ansari, F.A.; Ahmad, I. Prospects of Essential Oils in Controlling Pathogenic Biofilm. In New Look to Phytomedicine; Elsevier: Amsterdam, The Netherlands, 2019; pp. 203–236. [Google Scholar]
  25. Williams, L. Essential Oils with High Antimicrobial Activity for Therapeutic Use. Int. J. Aromather. 1998, 8, 30–40. [Google Scholar] [CrossRef]
  26. Sferrazzo, G.; Palmeri, R.; Restuccia, C.; Parafati, L.; Siracusa, L.; Spampinato, M.; Carota, G.; Distefano, A.; di Rosa, M.; Tomasello, B.; et al. Mangifera Indica L. Leaves as a Potential Food Source of Phenolic Compounds with Biological Activity. Antioxidants 2022, 11, 1313. [Google Scholar] [CrossRef]
  27. Donga, S.; Bhadu, G.R.; Chanda, S. Antimicrobial, Antioxidant and Anticancer Activities of Gold Nanoparticles Green Synthesized Using Mangifera Indica Seed Aqueous Extract. Artif. Cells Nanomed. Biotechnol. 2020, 48, 1315–1325. [Google Scholar] [CrossRef] [PubMed]
  28. Cardenas, V.; Mendoza, R.; Chiong, L.; del Aguila, E.; Alvítez-Temoche, D.; Mayta-Tovalino, F. Comparison of the Antibacterial Activity of the Ethanol Extract vs Hydroalcoholic Extract of the Leaves of Mangifera Indica L. (Mango) in Different Concentrations: An In Vitro Study. J. Contemp. Dent. Pract. 2020, 21, 202–206. [Google Scholar] [CrossRef] [PubMed]
  29. Ramdan, B.; Mrid, R.B.; Ramdan, R.; El Karbane, M.; Nhiri, M. Promising Effects of Rosa Damascena Petal Extracts as Antioxidant and Antibacterial Agents. Pak. J. Pharm. Sci. 2021, 34, 1–8. [Google Scholar] [PubMed]
  30. Tanimoto, H.; Shigemura, K.; Osawa, K.; Kado, M.; Onishi, R.; Fang, S.-B.; Sung, S.-Y.; Miyara, T.; Fujisawa, M. Comparative Genetic Analysis of the Antimicrobial Susceptibilities and Virulence of Hypermucoviscous and Non-Hypermucoviscous ESBL-Producing Klebsiella Pneumoniae in Japan. J. Microbiol. Immunol. Infect. 2023, 56, 93–103. [Google Scholar] [CrossRef]
  31. Dhifi, W.; Bellili, S.; Jazi, S.; Bahloul, N.; Mnif, W. Essential Oils’ Chemical Characterization and Investigation of Some Biological Activities: A Critical Review. Medicines 2016, 3, 25. [Google Scholar] [CrossRef] [Green Version]
  32. Lemberkovics, E.; Kéry, A.; Simándi, B.; Kakasy, A.; Balázs, A.; Héthelyi, E.; Szoke, E. Influence of Extraction Methods on the Composition of Essential Oils. Acta Pharm. Hung. 2004, 74, 166–170. [Google Scholar]
  33. Marino, M.; Bersani, C.; Comi, G. Antimicrobial Activity of the Essential Oils of Thymus Vulgaris L. Measured Using a Bioimpedometric Method. J. Food Prot. 1999, 62, 1017–1023. [Google Scholar] [CrossRef]
  34. Marchese, A.; Orhan, I.E.; Daglia, M.; Barbieri, R.; Di Lorenzo, A.; Nabavi, S.F.; Gortzi, O.; Izadi, M.; Nabavi, S.M. Antibacterial and Antifungal Activities of Thymol: A Brief Review of the Literature. Food Chem. 2016, 210, 402–414. [Google Scholar] [CrossRef] [PubMed]
  35. Mączka, W.; Duda-Madej, A.; Górny, A.; Grabarczyk, M.; Wińska, K. Can Eucalyptol Replace Antibiotics? Molecules 2021, 26, 4933. [Google Scholar] [CrossRef] [PubMed]
  36. Kamatou, G.P.P.; Vermaak, I.; Viljoen, A.M.; Lawrence, B.M. Menthol: A Simple Monoterpene with Remarkable Biological Properties. Phytochemistry 2013, 96, 15–25. [Google Scholar] [CrossRef] [PubMed]
  37. Abozid, M.M.; Asker, M.M. Chemical Composition, Antioxidant and Antimicrobial Activity of the Essential Oil of the Thyme and Rosemary. Int. J. Acad. Res. 2013, 5, 186–195. [Google Scholar] [CrossRef]
  38. Rašković, A.; Milanović, I.; Pavlović, N.; Ćebović, T.; Vukmirović, S.; Mikov, M. Antioxidant Activity of Rosemary (Rosmarinus Officinalis L.) Essential Oil and Its Hepatoprotective Potential. BMC Complement Altern. Med. 2014, 14, 225. [Google Scholar] [CrossRef] [Green Version]
  39. Sienkiewicz, M.; Łysakowska, M.; Pastuszka, M.; Bienias, W.; Kowalczyk, E. The Potential of Use Basil and Rosemary Essential Oils as Effective Antibacterial Agents. Molecules 2013, 18, 9334–9351. [Google Scholar] [CrossRef] [Green Version]
  40. Schmidt, E.; Bail, S.; Buchbauer, G.; Stoilova, I.; Atanasova, T.; Stoyanova, A.; Krastanov, A.; Jirovetz, L. Chemical Composition, Olfactory Evaluation and Antioxidant Effects of Essential Oil from Mentha x Piperita. Nat. Prod. Commun. 2009, 4, 1934578X0900400. [Google Scholar] [CrossRef] [Green Version]
  41. Negi, P.S.; Jayaprakasha, G.K.; Jagan Mohan Rao, L.; Sakariah, K.K. Antibacterial Activity of Turmeric Oil: A Byproduct from Curcumin Manufacture. J. Agric. Food Chem. 1999, 47, 4297–4300. [Google Scholar] [CrossRef]
  42. Kapoor, G.; Saigal, S.; Elongavan, A. Action and Resistance Mechanisms of Antibiotics: A Guide for Clinicians. J. Anaesthesiol. Clin. Pharm. Pharmacol. 2017, 33, 300. [Google Scholar] [CrossRef]
  43. Hriouech, S.; Akhmouch, A.A.; Mzabi, A.; Chefchaou, H.; Tanghort, M.; Oumokhtar, B.; Chami, N.; Remmal, A. The Antistaphylococcal Activity of Amoxicillin/Clavulanic Acid, Gentamicin, and 1,8-Cineole Alone or in Combination and Their Efficacy through a Rabbit Model of Methicillin-Resistant Staphylococcus Aureus Osteomyelitis. Evid.-Based Complement. Altern. Med. 2020, 2020, 4271017. [Google Scholar] [CrossRef]
  44. Reichling, J. Anti-Biofilm and Virulence Factor-Reducing Activities of Essential Oils and Oil Components as a Possible Option for Bacterial Infection Control. Planta Med. 2020, 86, 520–537. [Google Scholar] [CrossRef]
  45. Chouhan, S.; Sharma, K.; Guleria, S. Antimicrobial Activity of Some Essential Oils—Present Status and Future Perspectives. Medicines 2017, 4, 58. [Google Scholar] [CrossRef] [Green Version]
  46. Rai, M.; Paralikar, P.; Jogee, P.; Agarkar, G.; Ingle, A.P.; Derita, M.; Zacchino, S. Synergistic Antimicrobial Potential of Essential Oils in Combination with Nanoparticles: Emerging Trends and Future Perspectives. Int. J. Pharm. 2017, 519, 67–78. [Google Scholar] [CrossRef]
  47. Nair, A.; Mallya, R.; Suvarna, V.; Khan, T.A.; Momin, M.; Omri, A. Nanoparticles-Attractive Carriers of Antimicrobial Essential Oils. Antibiotics 2022, 11, 108. [Google Scholar] [CrossRef]
  48. Schiffelers, R.M.; Storm, G.; ten Kate, M.T.; Stearne-Cullen, L.E.; den Hollander, J.G.; Verbrugh, H.A.; Bakker-Woudenberg, I.A. In Vivo Synergistic Interaction of Liposome-Coencapsulated Gentamicin and Ceftazidime. J. Pharm. Pharmacol. Exp. Ther. 2001, 298, 369–375. [Google Scholar]
  49. Masango, P. Cleaner Production of Essential Oils by Steam Distillation. J. Clean. Prod. 2005, 13, 833–839. [Google Scholar] [CrossRef]
  50. Cruz-Córdova, A.; Esteban-Kenel, V.; Espinosa-Mazariego, K.; Ochoa, S.A.; Moreno Espinosa, S.; de la Garza Elhain, A.; Fernández Rendón, E.; López Villegas, E.O.; Xicohtencatl-Cortes, J. Pathogenic Determinants of Clinical Klebsiella Pneumoniae Strains Associated with Their Persistence in the Hospital Environment. Bol. Med. Hosp. Infant. Mex. 2014, 71, 15–24. [Google Scholar]
  51. Elmi, S.Y.K.; Ashour, M.S.; Alsewy, F.Z.; Abd El Moez Azzam, N.F. Phenotypic and Genotypic Detection of Extended Spectrum β-Lactamases among Escherichia Coli and Klebsiella Pneumoniae Isolates from Type 2 Diabetic Patients with Urinary Tract Infections. Afr. Health Sci. 2021, 21, 497–504. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 16 00839 g001 550
Figure 1. Antimicrobial Activity of EOs against different resistant profile Kp strains. Disc diffusion test of inhibition growth of Susceptible (A), Intermediate (B), Resistant (C), and reference ATCC 700603 (D) strains in the presence of EOs. Ceftazidime (CAZ) was used as a positive control. ** p < 0.01. Pointed line: Breakpoint is considered an effective antimicrobial activity for EOs. Median was identified by the line in each bar, points (⋅) represent each single data point and cross (x) represent outliers.
Figure 1. Antimicrobial Activity of EOs against different resistant profile Kp strains. Disc diffusion test of inhibition growth of Susceptible (A), Intermediate (B), Resistant (C), and reference ATCC 700603 (D) strains in the presence of EOs. Ceftazidime (CAZ) was used as a positive control. ** p < 0.01. Pointed line: Breakpoint is considered an effective antimicrobial activity for EOs. Median was identified by the line in each bar, points (⋅) represent each single data point and cross (x) represent outliers.
Pharmaceuticals 16 00839 g001
Pharmaceuticals 16 00839 g002 550
Figure 2. (A). Minimum inhibitory concentration (MIC) and (B). Minimum bactericidal concentration (MBC) of the EOs against Kp strains. Median was identified by the line in each bar, points (⋅) represent each single data point and cross (x) represent outliers.
Figure 2. (A). Minimum inhibitory concentration (MIC) and (B). Minimum bactericidal concentration (MBC) of the EOs against Kp strains. Median was identified by the line in each bar, points (⋅) represent each single data point and cross (x) represent outliers.
Pharmaceuticals 16 00839 g002
Pharmaceuticals 16 00839 g003 550
Figure 3. Effect of EOs on Ceftazidime (CAZ) MIC and MBC concentration. (A). Minimum Inhibitory Concentrations (MIC) and (B). Minimum Bactericidal Concentration (MBC) of Ceftazidime is reduced in the presence of the EOs. Median was identified by the line in each bar, points (⋅) represent each single data point and cross (x) represent outliers. * p < 0.05.
Figure 3. Effect of EOs on Ceftazidime (CAZ) MIC and MBC concentration. (A). Minimum Inhibitory Concentrations (MIC) and (B). Minimum Bactericidal Concentration (MBC) of Ceftazidime is reduced in the presence of the EOs. Median was identified by the line in each bar, points (⋅) represent each single data point and cross (x) represent outliers. * p < 0.05.
Pharmaceuticals 16 00839 g003
Pharmaceuticals 16 00839 g004 550
Figure 4. Effect of EOs on Gentamicin (GEN) MIC and MBC concentration. (A). Minimum Inhibitory Concentrations (MIC) and (B) Minimum Bactericidal Concentration (MBC) of GEN is reduced in the presence of the EOs. Median was identified by the line in each bar, points (⋅) represent each single data point and cross (x) represent outliers. * p < 0.05.
Figure 4. Effect of EOs on Gentamicin (GEN) MIC and MBC concentration. (A). Minimum Inhibitory Concentrations (MIC) and (B) Minimum Bactericidal Concentration (MBC) of GEN is reduced in the presence of the EOs. Median was identified by the line in each bar, points (⋅) represent each single data point and cross (x) represent outliers. * p < 0.05.
Pharmaceuticals 16 00839 g004
Pharmaceuticals 16 00839 g005 550
Figure 5. Effect of EOs over Ciprofloxacin (CIP) MIC and MBC concentration. (A). Minimum Inhibitory Concentrations (MIC) and (B). Minimum Bactericidal Concentration (MBC) of GEN is reduced in the presence of the EOs. Median was identified by the line in each bar, points (⋅) represent each single data point and cross (x) represent outliers. * p < 0.05, ** p < 0.01.
Figure 5. Effect of EOs over Ciprofloxacin (CIP) MIC and MBC concentration. (A). Minimum Inhibitory Concentrations (MIC) and (B). Minimum Bactericidal Concentration (MBC) of GEN is reduced in the presence of the EOs. Median was identified by the line in each bar, points (⋅) represent each single data point and cross (x) represent outliers. * p < 0.05, ** p < 0.01.
Pharmaceuticals 16 00839 g005
Pharmaceuticals 16 00839 g006 550
Figure 6. Decrease in hypermucoviscosity phenotype in Kp strains induced by EOs. String test of hypermucoviscosity strains in the absence (Control) and presence of EOs. ** p < 0.01.
Figure 6. Decrease in hypermucoviscosity phenotype in Kp strains induced by EOs. String test of hypermucoviscosity strains in the absence (Control) and presence of EOs. ** p < 0.01.
Pharmaceuticals 16 00839 g006
Pharmaceuticals 16 00839 g007 550
Figure 7. Mechanism of Action of the Synergic Effect of EOs with Antibiotics. The liposoluble nature of EOs affects the components involved with hypermucoviscosity phenotype (biofilm, capsule, siderophores, Lipopolysaccharides), which act as a physical barrier for antibiotics. When the hypermucoviscosity phenotype is affected, antibiotics could enter in the bacteria, and in synergy with EOs, induce bacteria death.
Figure 7. Mechanism of Action of the Synergic Effect of EOs with Antibiotics. The liposoluble nature of EOs affects the components involved with hypermucoviscosity phenotype (biofilm, capsule, siderophores, Lipopolysaccharides), which act as a physical barrier for antibiotics. When the hypermucoviscosity phenotype is affected, antibiotics could enter in the bacteria, and in synergy with EOs, induce bacteria death.
Pharmaceuticals 16 00839 g007
Table
Table 1. Essential oils included in this study.
Table 1. Essential oils included in this study.
Common NameScientific NamePart UsedExtraction Method
ThymeThymus vulgarisLeafSteam Distillation
PeppermintMentha piperitaLeaf/stemSteam Distillation
RosemaryRosmarinus officinalisFlower, leafSteam Distillation
TurmericCurcuma longaRhizomeSteam distillation
Table
Table 2. Major constituents of thyme, rosemary, turmeric, and peppermint EOs identified by GC/MS analysis.
Table 2. Major constituents of thyme, rosemary, turmeric, and peppermint EOs identified by GC/MS analysis.
Essential OilCompound *Retention TimeMatch% AreaStandardIK expIK rep
(min)
ThymeThymol13.3398.437.31Yes12961291
o-Cymene8.498.922.12No10291022
γ-Terpinene9.0699.511.97Yes10631060
Caryophyllene15.5998.84.37No14331419
Linalool9.8198.42.75Yes11021099
Carvacrol13.4797.42.43Yes13041299
β-Myrcene7.798.31.78No993991
(+)-4-Carene8.2396.91.66No10201009
Methyl carvacrol12.595.91.25No12491244
1-Octen-3-ol7.4596.91.22No980980
α-Pinene6.6196.51.16Yes937937
Camphene6.998.11.12No952951
Borneol11.3398.11.06No11831167
Camphor10.7497.50.91No11511142
D-Limonene8.4791.60.71Yes10321018
trans-4-Thuja-nol9.2294.50.71No10711070
Caryophyllene oxide18.1388.20.64No16001581
α-Thujene6.4794.80.49No930929
(+)-δ-Cadinene17.1682.40.35No15341524
Eucalyptol8.5386.40.3Yes10361032
(+)-epi-Bicyclosesquiphellandrene17.0584.30.26No15271435
p-Mentha-2,4-(8)-diene9.6388.20.25No10921004
RosemaryEucalyptol8.5499.843.28Yes10361032
(+)-2-Bornano-ne10.7499.413.34No11511143
α-Pinene6.6199.313.17Yes937937
Caryophyllene15.5999.34.97No14331419
β-Pinene7.4697.54.67Yes981943
Camphene6.998.74.54No952951
Borneol11.3397.23.51No11721167
D-Limonene8.48862.16Yes10331018
α-Terpineol11.5690.042.15Yes11951189
o-Cymene8.3997.71.53No10281022
β-Myrcene7.798.21.16No993991
Linalool9.8195.60.97Yes11021099
Bornyl acetate13.2795.80.71No12931284
Terpinen-4-ol11.3390.040.69Yes11831182
δ-Terpinene9.0696.10.67Yes10631060
(+)-4-Carene8.2396.40.52No10201009
Humulene16.1386.20.41No14671454
Isoterpinolene9.6491.70.31No10931004
β-Phellandre-ne6.3887.80.16No9251031
α-Thujene6.4790.010.15No930929
PeppermintMenthol11.2699.838.19No11791164
D-menthone10.9199.322.96No11601166
p-Menthan-1-ol11.0995.28.39No11701178
Eucalyptol8.5399.26.09Yes10361032
D-Limonene8.4796.82.15Yes10321018
Caryophyllene15.5997.31.81No14331419
β-Myrcene7.782.51.78No993991
Pulegone12.4797.81.67No12471237
L-terpinen-4-ol11.34931.3No11831182
β-Pinene7.4693.71.23Yes981943
α-Pinene6.6195.50.83Yes937937
dl-menthol11.4494.70.81No11891174
Caryophyllene oxide18.1387.40.68No16001581
o-Cymene8.3895.30.67No10281022
Piperitone12.7294.30.59No12611253
α-Terpineol11.5787.70.56Yes11961189
Mintlactone16.7780.80.52No15081500
δ-Terpinene9.0692.40.47Yes10631060
Cadina-1(6),4-diene17.1686.90.4No15341469
Linalool9.8183.60.31Yes11021099
β-Bourbonene15.0189.60.27No13961384
α-Thujene6.4792.10.25No930929
3-Octanol7.7888.90.25No997994
cis-Muurola-4(14),5-diene16.4583.50.25No14871435
Turmericar-Turmerone19.2297.740.4No16771644
Tumerone19.289816.36No16821632
α-Curcumene16.5994.53No14911483
Zingiberene16.6997.34.25No15031495
β-Sesquiphellandrene17.1497.13.15No15331524
(E)-Atlantone20.797.62.54No17861773
β-Bisabolene16.8996.91.25No15161509
(Z)-γ-Atlanto-ne19.5991.50.85No17041699
γ-Curcumene16.4585.70.75No14871480
Caryophyllene15.5991.10.67No14331419
7-epi-Bisabol-1-one20.33920.63No17591747
o-Cymene8.3896.40.53No10281022
Dicumene16.8483.60.48No15132021
Eucalyptol8.5388.20.38Yes10361032
2-Cyclohexen-1-one,3,4,4-tri-methyl17.6581.80.31No15681198
α-Phellandre-ne7.9993.50.26No10081005
Humulene16.1381.80.26No14671454
(+)-4-Carene9.6488.60.21No10931009
* The essential oil constituents were characterized by matching their mass spectra with compound library NIST. IK exp—Kováts retention index experimental. IK rep—Kováts retention index reported.
Table
Table 3. Fractional Inhibitory Concentration Index (FICI) of Ceftazidime and EOs against Klebsiella pneumoniae strains. The FICI was considered to indicate a synergistic effect if its value was ≤0.5, additive if it was from >0.5 to ≤1, indifferent if it was from >1.0 to ≤4, and antagonistic if it was >4.
Table 3. Fractional Inhibitory Concentration Index (FICI) of Ceftazidime and EOs against Klebsiella pneumoniae strains. The FICI was considered to indicate a synergistic effect if its value was ≤0.5, additive if it was from >0.5 to ≤1, indifferent if it was from >1.0 to ≤4, and antagonistic if it was >4.
Kp Strain640U889U126U98LCR338U537U1971U197U182DATCC 700603Mean FICI
CAZ + thyme0.3330.3330.0830.3330.0830.3330.3330.3330.1670.1670.250
CAZ + turmeric0.6250.5000.7500.5080.2810.5160.2520.5020.5161.0000.545
CAZ + rosemary0.7500.5001.0000.5080.2660.5160.2540.5020.5020.5630.536
CAZ + peppermint0.3750.5000.3130.2660.3130.2660.2520.5000.2500.5310.357
Table
Table 4. Fractional Inhibitory Concentration Index (FICI) of Gentamicin (GEN) and EOs against Klebsiella pneumoniae strains. The FICI indicated a synergistic effect if its value was ≤0.5, additive if it was from >0.5 to ≤1, indifferent if it was from >1.0 to ≤4, and antagonism if it was >4.
Table 4. Fractional Inhibitory Concentration Index (FICI) of Gentamicin (GEN) and EOs against Klebsiella pneumoniae strains. The FICI indicated a synergistic effect if its value was ≤0.5, additive if it was from >0.5 to ≤1, indifferent if it was from >1.0 to ≤4, and antagonism if it was >4.
Kp Strain889U98LCR197UMean FICI
GEN + thyme0.3330.3330.5630.410
GEN + turmeric2.2500.3750.6251.083
GEN + rosemary0.2500.5000.6250.458
GEN + peppermint0.0600.2500.5160.275
Table
Table 5. Fractional Inhibitory Concentration Index (FICI) of Ciprofloxacin (CIP) and EOs against Klebsiella pneumoniae strains. The FICI was the synergistic effect if its value was ≤0.5, additive if it was from >0.5 to ≤1, indifferent if it was from >1.0 to ≤4, and antagonism if it was >4.
Table 5. Fractional Inhibitory Concentration Index (FICI) of Ciprofloxacin (CIP) and EOs against Klebsiella pneumoniae strains. The FICI was the synergistic effect if its value was ≤0.5, additive if it was from >0.5 to ≤1, indifferent if it was from >1.0 to ≤4, and antagonism if it was >4.
Kp Strain197U817LCR910LCRMean FICI
CIP + thyme0.3330.3330.5000.389
CIP + turmeric0.7501.2500.5000.835
CIP + rosemary0.4900.3700.5160.459
CIP + peppermint0.1800.2500.500.311
Table
Table 6. Strain resistance classification based on resistance patterns. LRS: Low Resistant Strain, MRS: Medium Resistant Strain, HRS: High Resistant Strain, CPD: cefpodoxime, CRO: ceftriaxone, CAZ: Ceftazidime, CEF: cefepime, CIP: ciprofloxacin, ATM: aztreonam, AMI: amikacin, GEN: Gentamycin, STX: trimethoprim/sulfamethoxazole. Breakpoints were established as reported by CLSI.
Table 6. Strain resistance classification based on resistance patterns. LRS: Low Resistant Strain, MRS: Medium Resistant Strain, HRS: High Resistant Strain, CPD: cefpodoxime, CRO: ceftriaxone, CAZ: Ceftazidime, CEF: cefepime, CIP: ciprofloxacin, ATM: aztreonam, AMI: amikacin, GEN: Gentamycin, STX: trimethoprim/sulfamethoxazole. Breakpoints were established as reported by CLSI.
StrainResistance ClassificationResistantIntermediateSusceptible
640ULRSATM-CPD, CRO, CAZ, CEF, CIP, AMI, GEN, STX
889ULRSSTX-CPD, CRO, CAZ, CEF, CIP, ATM, AMI, GEN
126ULRSATM-CPD, CRO, CAZ, CEF, CIP, AMI, GEN, STX
98LCRMRSCPDCAZ, CRO, GENCEF, CIP, ATM, AMI, STX
338UMRSCPD, GENCRO, CAZ, ATM, STXCEF, CIP, AMI
537U1MRSCPDCRO, CAZ, ATM, AMI, CEF, CIP, GEN, STX
971UHRSCPD, CRO, CAZ, CEF, ATM, AMI, GEN, CIP, STX
197UHRSCPD, CRO, CAZ, CEF, ATM, AMI, GEN, STX CIP
182DHRSCPD, CRO, CAZ, CEF, ATM, AMI, STXCIP, GEN
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Romo-Castillo, M.; Flores-Bautista, V.A.; Guzmán-Gutiérrez, S.L.; Reyes-Chilpa, R.; León-Santiago, M.; Luna-Pineda, V.M. Synergy of Plant Essential Oils in Antibiotic Therapy to Combat Klebsiella pneumoniae Infections. Pharmaceuticals 2023, 16, 839. https://doi.org/10.3390/ph16060839

AMA Style

Romo-Castillo M, Flores-Bautista VA, Guzmán-Gutiérrez SL, Reyes-Chilpa R, León-Santiago M, Luna-Pineda VM. Synergy of Plant Essential Oils in Antibiotic Therapy to Combat Klebsiella pneumoniae Infections. Pharmaceuticals. 2023; 16(6):839. https://doi.org/10.3390/ph16060839

Chicago/Turabian Style

Romo-Castillo, Mariana, Victor Andrés Flores-Bautista, Silvia Laura Guzmán-Gutiérrez, Ricardo Reyes-Chilpa, Mayra León-Santiago, and Victor Manuel Luna-Pineda. 2023. "Synergy of Plant Essential Oils in Antibiotic Therapy to Combat Klebsiella pneumoniae Infections" Pharmaceuticals 16, no. 6: 839. https://doi.org/10.3390/ph16060839

APA Style

Romo-Castillo, M., Flores-Bautista, V. A., Guzmán-Gutiérrez, S. L., Reyes-Chilpa, R., León-Santiago, M., & Luna-Pineda, V. M. (2023). Synergy of Plant Essential Oils in Antibiotic Therapy to Combat Klebsiella pneumoniae Infections. Pharmaceuticals, 16(6), 839. https://doi.org/10.3390/ph16060839

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop